Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Emerg Infect Dis ; 30(1): 129-132, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38147044

RESUMEN

The site of enterohepatic Helicobacter colonization/infection in humans is still unknown. We report microbiologically and histopathologically confirmed H. fennelliae localization in the large intestine in an immunocompromised patient in Japan. This case contributes to better understanding of the life cycle of enterohepatic Helicobacter species.


Asunto(s)
Helicobacter , Intestinos , Humanos , Japón , Helicobacter/genética , Huésped Inmunocomprometido
2.
Nutr Metab Cardiovasc Dis ; 18(7): 483-91, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17964767

RESUMEN

BACKGROUND AND AIMS: Dietary therapy using phytosterols can reinforce statin treatment; however the value of a low-dose combination of those agents remains to be investigated. Plant sterols (PS), dissolved in diacylglycerol (DAG) oil, (PS/DAG) can be effective at a relatively low dose. The objective of the present study was to examine the effect of PS/DAG oil on blood cholesterol concentrations in hypercholesterolemic outpatients on low-dose pravastatin (10 mg/day). METHODS AND RESULTS: The patients (n=61) were randomly assigned to one of three groups, who consumed TAG (control), DAG or PS/DAG oil. The average intake of PS from the PS/DAG oil during the test period was significantly higher than that for TAG and DAG oils (502 vs. 49 and 38 mg/day, P<0.05). Significant cholesterol-lowering effects from the baseline were observed in the case of the PS/DAG oil treatment alone. Changes in low-density lipoprotein (LDL) cholesterol were inversely correlated with baseline serum campesterol concentrations (r=-0.560, P<0.05), but not baseline LDL cholesterol concentrations. In addition, serum apolipoprotein B concentrations were reduced to a greater extent in subjects with high versus low levels of baseline campesterol (-13.2 mg/dL vs. -3.1 mg/dL, P<0.05). Furthermore, there was a mild, but significant reduction in serum lipoprotein (a) concentration from the baseline (-5.9 mg/dL), which was correlated with the reduction in serum apolipoprotein B concentration (r=0.596, P<0.05). CONCLUSION: A low-dose combination of PS/DAG oil and pravastatin may be a useful strategy for further ameliorating blood cholesterol and lipoprotein (a) concentrations for hypercholesterolemic patients with a low response to pravastatin.


Asunto(s)
Anticolesterolemiantes/uso terapéutico , Colesterol/sangre , Hipercolesterolemia/tratamiento farmacológico , Fitosteroles/uso terapéutico , Pravastatina/uso terapéutico , Adulto , Anciano , Diglicéridos/administración & dosificación , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Sinergismo Farmacológico , Femenino , Humanos , Hipercolesterolemia/sangre , Lipoproteína(a)/sangre , Masculino , Persona de Mediana Edad , Fitosteroles/administración & dosificación , Solubilidad , Resultado del Tratamiento , Triglicéridos/administración & dosificación , Triglicéridos/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA